Poseida Therapeutics (PSTX)

8.68 +0.05 (0.58%)

Chart
Today 6M 1Y 5Y

Latest Headlines

Form 4 Poseida Therapeutics, For: Jan 08 Filed by: Spear Matthew A. January 11, 2021 5:00 PM - SEC Filing Poseida Therapeutics to Participate in SternIR Virtual Corporate Access Event January 4, 2021 8:00 AM - PR NewsWire Form 3 Poseida Therapeutics, For: Dec 16 Filed by: Corning Luke December 28, 2020 4:07 PM - SEC Filing Form SC 13D Poseida Therapeutics, Filed by: Pentwater Capital Management LP December 28, 2020 4:05 PM - SEC Filing Poseida Therapeutics Added to NASDAQ Biotechnology Index December 18, 2020 8:00 AM - PR NewsWire Poseida Therapeutics (PSTX) Adds Luke Corning to Board December 17, 2020 8:12 AM - StreetInsider Form 8-K Poseida Therapeutics, For: Dec 16 December 17, 2020 8:11 AM - SEC Filing Poseida Therapeutics Appoints Luke Corning to Board of Directors December 17, 2020 8:00 AM - PR NewsWire Form 8-K Poseida Therapeutics, For: Dec 05 December 7, 2020 8:01 AM - SEC Filing Poseida Therapeutics Provides Update on Phase 1 Trial of P-BCMA-101 at the 2020 American Society of Hematology Annual Meeting December 5, 2020 1:45 PM - PR NewsWire Form 10-Q Poseida Therapeutics, For: Sep 30 November 12, 2020 4:18 PM - SEC Filing Form 8-K Poseida Therapeutics, For: Nov 12 November 12, 2020 4:13 PM - SEC Filing Poseida Therapeutics Reports Operational Update and Financial Results for Third Quarter 2020 November 12, 2020 4:05 PM - PR NewsWire Form 8-K Poseida Therapeutics, For: Nov 02 November 2, 2020 8:11 AM - SEC Filing Poseida Therapeutics (PSTX) Reports Clinical Hold Lifted on Phase I Autologous CAR-T Study in Prostate Cancer November 2, 2020 8:04 AM - StreetInsider Poseida Therapeutics Announces Clinical Hold Lifted on Phase I Autologous CAR-T Study in Prostate Cancer November 2, 2020 8:00 AM - PR NewsWire Poseida Therapeutics (PSTX), TScan Therapeutics Announce Research Collaboration and License Agreement to Explore Developing Allogeneic T Cell Receptor Therapies for the Treatment of COVID-19 October 21, 2020 8:09 AM - StreetInsider Poseida Therapeutics and TScan Therapeutics Announce Research Collaboration and License Agreement to Explore Developing Allogeneic T Cell Receptor Therapies for the Treatment of COVID-19 October 21, 2020 8:00 AM - PR NewsWire Full Article List